A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Exploring minzasolmin effect on digital measures captured by the Verily Study Watch in a subset of the ORCHESTRA trial participants
Objective: To investigate the progression over time and the effect of minzasolmin on digital outcomes collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small…Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings
Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…NIH funds Gut-Brain Parkinson’s Disease Consortium
Objective: Describe the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) multicenter (UO1) Consortium on PD Gut-Brain Communication. Background: A 2024 Notice of Funding…Dual-task gait digital assessment unmask the association between dopaminergic deficits and gait parameters in early and prodromal Parkinson’s Disease
Objective: to explore the relationship between dopaminergic deficits and digital gait parameters alterations in de novo PD and iRBD Background: gait alterations are common features…Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task
Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study
Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…Unraveling the Intertwined Relationship of DBS, Parkinson’s Disease Subtype and LEDD: A Retrospective Study
Objective: To assess the impact of deep brain stimulation (DBS) target and Parkinson’s disease (PD) motor subtype on the total levodopa equivalent daily dose (LEDD)…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 181
- Next Page »